Global Antiemetics Market By Drug Class (5-HT3 Receptor Antagonists, Cannabinoids, Benzodiazepines, Glucocorticoids, Dopamine Receptor Antagonists, Neurokinin (NK1) Receptor Antagonists, Antihistamines, Others), By Application (Chemotherapy and Radiation therapy, Motion Sickness, Stomach Flu, Pregnancy, Gastroenteritis, Surgery, Others), By End User (Hospitals, Clinics, Pharmacies, Others), By Route of Administration (Oral, Injectable, Others), By Sales Channel (Online, Offline), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Antiemetic pharmaceuticals are used to treat nausea and vomiting, which are side effects of other medications. This could include anesthetic medicines used during surgery or chemotherapy for cancer. Antiemetic medications are also used to treat nausea and vomiting caused by motion sickness, morning sickness during pregnancy, severe stomach flu (gastroenteritis), and other illnesses. Antiemetics acts by inhibiting specific receptors that respond to neurotransmitter molecules including serotonin, dopamine, and histamine in the brain circuits implicated in vomiting. Several serotonin 5-HT3 antagonists have been permitted and prescribed as antiemetics, particularly for the treatment of chemotherapy-induced nausea and vomiting in cancer patients, as well as postoperative nausea and vomiting. The growing number of gastroenteritis patients is a critical element driving the antiemetics market growth. Also, increased number of operations and rising healthcare spending due to rising disposable income is likely to contribute for market expansion over the forecasted period. Furthermore, increased technology advancements and modernization in the healthcare sector would generate new chances for the antiemetics market in the coming years. Major companies also contribute to the growth of the market and are launching new products in the market. For instance, Acacia Pharma Group Plc, a hospital pharmaceutical company involved in the development and commercialization of new products intended to improve the care of patients undergoing major treatments. They announced in February 2020 that the US Food and Drug Administration (FDA) has approved BARHEMSYS (amisulpride injection) for the treatment and prevention of postoperative nausea and vomiting (PONV) in adult patients. BARHEMSYS is an antiemetic to be licensed for the treatment of PONV in patients who have not responded to mainstream prophylaxis.
The COVID-19 pandemic had affected about 192 million people globally as of July 22, 2021, resulting in 4.13 million deaths. Various government bodies declared strict lockdowns in order to restrict the spread of the disease. While this disorder primarily affects the lungs, causing pneumonia and acute respiratory distress syndrome, it also has an adverse effect on other chronic conditions. Antiemetics pharmaceuticals were popular during the pandemic as a medical solution to decrease SARS-CoV-2-induced nausea and vomiting while also balancing prescription side effects. Furthermore, the increased promise of innovation in drug development will provide new opportunities for the growth of antiemetics market participants in the healthcare sector in the near future.
In terms of revenue, the antiemetics market was valued at US$ 4871.21 Mn in 2021 growing at a CAGR of 7.21% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Antiemetics Market Revenue & Forecast, (US$ Million), 2015 – 2030
Drug Class Outlook:
Based on drug class, the global antiemetics market has been primarily segmented into 5-ht3 receptor antagonists, cannabinoids, benzodiazepines, glucocorticoids, dopamine receptor antagonists, neurokinin (nk1) receptor antagonists, antihistamines, and others. 5-HT3 Receptor Antagonists is one of the prominent segments in the market. 5-ht3 receptor antagonists are medications used to prevent and treat nausea and vomiting, notably nausea and vomiting caused by chemotherapy, radiation therapy, or postoperatively. For patients receiving chemotherapy drugs with moderate to high antiemetic potential, selective 5HT3 receptor antagonists constitute the cornerstone of antiemetic therapy.
Application Outlook:
Based on application, the global antiemetics market has been segmented into chemotherapy and radiation therapy, motion sickness, stomach flu, pregnancy, gastroenteritis, surgery, and others. The chemotherapy and radiation therapy segment holds a significant share of the market in 2021, owing to technical improvements in chemotherapy and the rising incidence of cancer, which are the primary reasons driving the segment growth in the antiemetics market. Furthermore, advances in radiotherapy have aided in the creation of more effective, low-cost, and simple-to-use radiotherapy products with enhanced and precise radiation dose delivery to provide increased efficiency in tumor targeting.
End Users Outlook:
Based on end-users, the global antiemetics market has been segmented into hospitals, clinics, pharmacies, and others. The clinics segment is projected to be the emerging segment in the coming years because of the increasing demand for specialty clinics. Furthermore, the prominence of urgent care clinic business model is growing in developed economies. Urgent care centers are convenient, on-demand care outlets similar to walk-in retail clinics, but instead of treating low-acuity conditions like bronchitis and minor infections, urgent care clinics are equipped to treat more serious ailments.
Route of Administration Outlook:
Based on route of administration, the global antiemetics market has been segmented into oral, injectable, and others. Injectable route of administration is projected to fastest-growing segment over the forecast period 2022 – 2030, owing to its advantages such as short latent time and ability to rapidly improve a drug's action. In addition, when compared to oral methods, it delivers a faster onset of action. Merck also offers single-dose EMEND (fosaprepitant dimeglumine) injection. In adults taking initial and repeat doses of mildly emetogenic chemotherapy, Merck's substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medications, to avoid delayed nausea and vomiting (MEC).
Sales Channel Outlook:
Based on sales channels, the global antiemetics market has been segmented into online and offline. The offline sales channel holds a substantial share of the market in 2021. Traditional brick-and-mortar businesses that serve customers in actual locations, such as pharmacies and specialty retail stores, are examples of offline ventures. The ability for customers to form personal contacts with the firm, which can build loyalty, is one of the benefits of offline sales.
Region Outlook:
Based on regions, North America held the highest share of the global antiemetics market in 2021, owing to increasing medical spending and the region's embrace of sophisticated technology. The healthcare industry's key players continue to invest in drug discovery, resulting in continuous advancements in healthcare technology. Furthermore, the presence of big companies contributes to the market's growth in this region. The strong prevalence of the patient pool undergoing chemotherapy and the availability of the basic hospital infrastructure in the North American region contributes to the growth of the market.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of the global antiemetics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the global antiemetics market are
- Acacia Pharma Group Plc
- Astellas Pharma Inc.
- Aurobindo Pharma
- Biostem Pharma
- Dr. Reddy’s Laboratories Ltd.
- Eisai Co., Ltd.
- F.Hoffmann-La Roche Limited
- Heron Therapeutics, Inc.
- Merck & Co., Inc.
- Novartis
- PAX HEALTHCARE
- Pfizer Inc
- Sanofi S.A.
- TerSera Therapeutics LLC
- Teva Pharmaceutical Industries Ltd.
- Other Market Participants
Global Antiemetics Market:
- By Drug Class
- 5-HT3 Receptor Antagonists
- Cannabinoids
- Benzodiazepines
- Glucocorticoids
- Dopamine Receptor Antagonists
- Neurokinin (NK1) Receptor Antagonists
- Antihistamines
- Others
- By Application
- Chemotherapy and Radiation therapy
- Motion Sickness
- Stomach Flu
- Pregnancy
- Gastroenteritis
- Surgery
- Others
- By End-User
- Hospitals
- Clinics
- Pharmacies
- Others
- By Route of Administration
- Oral
- Injectable
- Others
- By Sales Channel
- Online
- Offline
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Antiemetics Market
6.
Market
Synopsis: Antiemetics Market
7.
Antiemetics
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Antiemetics Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Antiemetics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Antiemetics Market
8.
Global
Antiemetics Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Antiemetics Market Revenue (US$ Mn)
8.2. Global Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
8.2.1. 5-HT3 Receptor Antagonists
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Cannabinoids
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. Benzodiazepines
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Glucocorticoids
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.2.5. Dopamine Receptor Antagonists
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 - 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 - 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 - 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 - 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 - 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 - 2030
8.2.6. Neurokinin (NK1) Receptor Antagonists
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 - 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 - 2030
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 - 2030
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 - 2030
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 - 2030
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 - 2030
8.2.7. Antihistamines
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.7.3.
Market
Forecast, 2022 - 2030
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1.
North
America
8.2.7.5.1.1. Market Estimation, 2015 - 2021
8.2.7.5.1.2. Market Forecast, 2022 - 2030
8.2.7.5.2.
Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2021
8.2.7.5.2.2. Market Forecast, 2022 - 2030
8.2.7.5.3.
Asia
Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2021
8.2.7.5.3.2. Market Forecast, 2022 - 2030
8.2.7.5.4.
Middle
East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2021
8.2.7.5.4.2. Market Forecast, 2022 - 2030
8.2.7.5.5.
Latin
America
8.2.7.5.5.1. Market Estimation, 2015 - 2021
8.2.7.5.5.2. Market Forecast, 2022 - 2030
8.2.8. Others
8.2.8.1.
Definition
8.2.8.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.8.3.
Market
Forecast, 2022 - 2030
8.2.8.4.
Compound
Annual Growth Rate (CAGR)
8.2.8.5.
Regional
Bifurcation
8.2.8.5.1.
North
America
8.2.8.5.1.1. Market Estimation, 2015 - 2021
8.2.8.5.1.2. Market Forecast, 2022 - 2030
8.2.8.5.2.
Europe
8.2.8.5.2.1. Market Estimation, 2015 - 2021
8.2.8.5.2.2. Market Forecast, 2022 - 2030
8.2.8.5.3.
Asia
Pacific
8.2.8.5.3.1. Market Estimation, 2015 - 2021
8.2.8.5.3.2. Market Forecast, 2022 - 2030
8.2.8.5.4.
Middle
East and Africa
8.2.8.5.4.1. Market Estimation, 2015 - 2021
8.2.8.5.4.2. Market Forecast, 2022 - 2030
8.2.8.5.5.
Latin
America
8.2.8.5.5.1. Market Estimation, 2015 - 2021
8.2.8.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Drug Class
9.
Global
Antiemetics Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
9.2.1. Chemotherapy and Radiation therapy
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Motion Sickness
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3. Stomach Flu
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4. Pregnancy
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5. Gastroenteritis
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.2.6. Surgery
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.6.3.
Market
Forecast, 2022 - 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 - 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 - 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 - 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 - 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 - 2030
9.2.7. Others
9.2.7.1.
Definition
9.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.7.3.
Market
Forecast, 2022 - 2030
9.2.7.4.
Compound
Annual Growth Rate (CAGR)
9.2.7.5.
Regional
Bifurcation
9.2.7.5.1.
North
America
9.2.7.5.1.1. Market Estimation, 2015 - 2021
9.2.7.5.1.2. Market Forecast, 2022 - 2030
9.2.7.5.2.
Europe
9.2.7.5.2.1. Market Estimation, 2015 - 2021
9.2.7.5.2.2. Market Forecast, 2022 - 2030
9.2.7.5.3.
Asia
Pacific
9.2.7.5.3.1. Market Estimation, 2015 - 2021
9.2.7.5.3.2. Market Forecast, 2022 - 2030
9.2.7.5.4.
Middle
East and Africa
9.2.7.5.4.1. Market Estimation, 2015 - 2021
9.2.7.5.4.2. Market Forecast, 2022 - 2030
9.2.7.5.5.
Latin
America
9.2.7.5.5.1. Market Estimation, 2015 - 2021
9.2.7.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Application
10. Global Antiemetics Market Analysis and
Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Clinics
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Pharmacies
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 -
2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By End-User
11. Global Antiemetics Market Analysis and
Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
11.2.1. Oral
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 -
2021
11.2.1.3. Market Forecast, 2022 - 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Injectable
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 -
2021
11.2.2.3. Market Forecast, 2022 - 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 -
2021
11.2.3.3. Market Forecast, 2022 - 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 - 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 - 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 - 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 - 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Route of Administration
12. Global Antiemetics Market Analysis and
Forecasts, 2022 – 2030
12.1. Overview
12.2. Global Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
12.2.1. Online
12.2.1.1. Definition
12.2.1.2. Market Estimation and Penetration, 2015 -
2021
12.2.1.3. Market Forecast, 2022 - 2030
12.2.1.4. Compound Annual Growth Rate (CAGR)
12.2.1.5. Regional Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market Estimation, 2015 - 2021
12.2.1.5.1.2. Market Forecast, 2022 - 2030
12.2.1.5.2. Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2021
12.2.1.5.2.2. Market Forecast, 2022 - 2030
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2021
12.2.1.5.3.2. Market Forecast, 2022 - 2030
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2021
12.2.1.5.4.2. Market Forecast, 2022 - 2030
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market Estimation, 2015 - 2021
12.2.1.5.5.2. Market Forecast, 2022 - 2030
12.2.2. Offline
12.2.2.1. Definition
12.2.2.2. Market Estimation and Penetration, 2015 -
2021
12.2.2.3. Market Forecast, 2022 - 2030
12.2.2.4. Compound Annual Growth Rate (CAGR)
12.2.2.5. Regional Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market Estimation, 2015 - 2021
12.2.2.5.1.2. Market Forecast, 2022 - 2030
12.2.2.5.2. Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2021
12.2.2.5.2.2. Market Forecast, 2022 - 2030
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2021
12.2.2.5.3.2. Market Forecast, 2022 - 2030
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2021
12.2.2.5.4.2. Market Forecast, 2022 - 2030
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market Estimation, 2015 - 2021
12.2.2.5.5.2. Market Forecast, 2022 - 2030
12.3. Key Segment for Channeling Investments
12.3.1. By Sales Channel
13. North America Antiemetics Market Analysis
and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. North America Antiemetics Market Revenue (US$
Mn)
13.2. North America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.2.1. 5-HT3 Receptor Antagonists
13.2.2. Cannabinoids
13.2.3. Benzodiazepines
13.2.4. Glucocorticoids
13.2.5. Dopamine Receptor Antagonists
13.2.6. Neurokinin (NK1) Receptor Antagonists
13.2.7. Antihistamines
13.2.8. Others
13.3. North America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
13.3.1. Chemotherapy and Radiation therapy
13.3.2. Motion Sickness
13.3.3. Stomach Flu
13.3.4. Pregnancy
13.3.5. Gastroenteritis
13.3.6. Surgery
13.3.7. Others
13.4. North America Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Pharmacies
13.4.4. Others
13.5. North America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.5.1. Oral
13.5.2. Injectable
13.5.3. Others
13.6. North America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
13.6.1. Online
13.6.2. Offline
13.7. North America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
13.7.1.1.1. 5-HT3 Receptor Antagonists
13.7.1.1.2. Cannabinoids
13.7.1.1.3. Benzodiazepines
13.7.1.1.4. Glucocorticoids
13.7.1.1.5. Dopamine Receptor Antagonists
13.7.1.1.6. Neurokinin (NK1) Receptor Antagonists
13.7.1.1.7. Antihistamines
13.7.1.1.8. Others
13.7.1.2. U.S Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
13.7.1.2.1. Chemotherapy and Radiation therapy
13.7.1.2.2. Motion Sickness
13.7.1.2.3. Stomach Flu
13.7.1.2.4. Pregnancy
13.7.1.2.5. Gastroenteritis
13.7.1.2.6. Surgery
13.7.1.2.7. Others
13.7.1.3. U.S Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.7.1.3.1. Hospitals
13.7.1.3.2. Clinics
13.7.1.3.3. Pharmacies
13.7.1.3.4. Others
13.7.1.4. U.S Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.7.1.4.1. Oral
13.7.1.4.2. Injectable
13.7.1.4.3. Others
13.7.1.5. U.S Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
13.7.1.5.1. Online
13.7.1.5.2. Offline
13.7.2. Canada
13.7.2.1. Canada Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
13.7.2.1.1. 5-HT3 Receptor Antagonists
13.7.2.1.2. Cannabinoids
13.7.2.1.3. Benzodiazepines
13.7.2.1.4. Glucocorticoids
13.7.2.1.5. Dopamine Receptor Antagonists
13.7.2.1.6. Neurokinin (NK1) Receptor Antagonists
13.7.2.1.7. Antihistamines
13.7.2.1.8. Others
13.7.2.2. Canada Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
13.7.2.2.1. Chemotherapy and Radiation therapy
13.7.2.2.2. Motion Sickness
13.7.2.2.3. Stomach Flu
13.7.2.2.4. Pregnancy
13.7.2.2.5. Gastroenteritis
13.7.2.2.6. Surgery
13.7.2.2.7. Others
13.7.2.3. Canada Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
13.7.2.3.1. Hospitals
13.7.2.3.2. Clinics
13.7.2.3.3. Pharmacies
13.7.2.3.4. Others
13.7.2.4. Canada Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.7.2.4.1. Oral
13.7.2.4.2. Injectable
13.7.2.4.3. Others
13.7.2.5. Canada Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
13.7.2.5.1. Online
13.7.2.5.2. Offline
13.7.3. Mexico
13.7.3.1. Mexico Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
13.7.3.1.1. 5-HT3 Receptor Antagonists
13.7.3.1.2. Cannabinoids
13.7.3.1.3. Benzodiazepines
13.7.3.1.4. Glucocorticoids
13.7.3.1.5. Dopamine Receptor Antagonists
13.7.3.1.6. Neurokinin (NK1) Receptor Antagonists
13.7.3.1.7. Antihistamines
13.7.3.1.8. Others
13.7.3.2. Mexico Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
13.7.3.2.1. Chemotherapy and Radiation therapy
13.7.3.2.2. Motion Sickness
13.7.3.2.3. Stomach Flu
13.7.3.2.4. Pregnancy
13.7.3.2.5. Gastroenteritis
13.7.3.2.6. Surgery
13.7.3.2.7. Others
13.7.3.3. Mexico Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
13.7.3.3.1. Hospitals
13.7.3.3.2. Clinics
13.7.3.3.3. Pharmacies
13.7.3.3.4. Others
13.7.3.4. Mexico Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.7.3.4.1. Oral
13.7.3.4.2. Injectable
13.7.3.4.3. Others
13.7.3.5. Mexico Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
13.7.3.5.1. Online
13.7.3.5.2. Offline
13.7.4. Rest of North America
13.7.4.1. Rest of North America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
13.7.4.1.1. 5-HT3 Receptor Antagonists
13.7.4.1.2. Cannabinoids
13.7.4.1.3. Benzodiazepines
13.7.4.1.4. Glucocorticoids
13.7.4.1.5. Dopamine Receptor Antagonists
13.7.4.1.6. Neurokinin (NK1) Receptor Antagonists
13.7.4.1.7. Antihistamines
13.7.4.1.8. Others
13.7.4.2. Rest of North America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Application
13.7.4.2.1. Chemotherapy and Radiation therapy
13.7.4.2.2. Motion Sickness
13.7.4.2.3. Stomach Flu
13.7.4.2.4. Pregnancy
13.7.4.2.5. Gastroenteritis
13.7.4.2.6. Surgery
13.7.4.2.7. Others
13.7.4.3. Rest of North America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By End-User
13.7.4.3.1. Hospitals
13.7.4.3.2. Clinics
13.7.4.3.3. Pharmacies
13.7.4.3.4. Others
13.7.4.4. Rest of North America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.4.4.1. Oral
13.7.4.4.2. Injectable
13.7.4.4.3. Others
13.7.4.5. Rest of North America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Sales Channel
13.7.4.5.1. Online
13.7.4.5.2. Offline
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Drug Class
13.8.3. By Application
13.8.4. By End-User
13.8.5. By Route of Administration
13.8.6. By Sales Channel
14. Europe Antiemetics Market Analysis and
Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Europe Antiemetics Market Revenue (US$ Mn)
14.2. Europe Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.2.1. 5-HT3 Receptor Antagonists
14.2.2. Cannabinoids
14.2.3. Benzodiazepines
14.2.4. Glucocorticoids
14.2.5. Dopamine Receptor Antagonists
14.2.6. Neurokinin (NK1) Receptor Antagonists
14.2.7. Antihistamines
14.2.8. Others
14.3. Europe Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
14.3.1. Chemotherapy and Radiation therapy
14.3.2. Motion Sickness
14.3.3. Stomach Flu
14.3.4. Pregnancy
14.3.5. Gastroenteritis
14.3.6. Surgery
14.3.7. Others
14.4. Europe Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Pharmacies
14.4.4. Others
14.5. Europe Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.5.1. Oral
14.5.2. Injectable
14.5.3. Others
14.6. Europe Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
14.6.1. Online
14.6.2. Offline
14.7. Europe Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Country
14.7.1. France
14.7.1.1. France Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
14.7.1.1.1. 5-HT3 Receptor Antagonists
14.7.1.1.2. Cannabinoids
14.7.1.1.3. Benzodiazepines
14.7.1.1.4. Glucocorticoids
14.7.1.1.5. Dopamine Receptor Antagonists
14.7.1.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.1.1.7. Antihistamines
14.7.1.1.8. Others
14.7.1.2. France Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.1.2.1. Chemotherapy and Radiation therapy
14.7.1.2.2. Motion Sickness
14.7.1.2.3. Stomach Flu
14.7.1.2.4. Pregnancy
14.7.1.2.5. Gastroenteritis
14.7.1.2.6. Surgery
14.7.1.2.7. Others
14.7.1.3. France Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
14.7.1.3.1. Hospitals
14.7.1.3.2. Clinics
14.7.1.3.3. Pharmacies
14.7.1.3.4. Others
14.7.1.4. France Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.1.4.1. Oral
14.7.1.4.2. Injectable
14.7.1.4.3. Others
14.7.1.5. France Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
14.7.1.5.1. Online
14.7.1.5.2. Offline
14.7.2. The UK
14.7.2.1. The UK Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
14.7.2.1.1. 5-HT3 Receptor Antagonists
14.7.2.1.2. Cannabinoids
14.7.2.1.3. Benzodiazepines
14.7.2.1.4. Glucocorticoids
14.7.2.1.5. Dopamine Receptor Antagonists
14.7.2.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.2.1.7. Antihistamines
14.7.2.1.8. Others
14.7.2.2. The UK Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
14.7.2.2.1. Chemotherapy and Radiation therapy
14.7.2.2.2. Motion Sickness
14.7.2.2.3. Stomach Flu
14.7.2.2.4. Pregnancy
14.7.2.2.5. Gastroenteritis
14.7.2.2.6. Surgery
14.7.2.2.7. Others
14.7.2.3. The UK Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
14.7.2.3.1. Hospitals
14.7.2.3.2. Clinics
14.7.2.3.3. Pharmacies
14.7.2.3.4. Others
14.7.2.4. The UK Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.2.4.1. Oral
14.7.2.4.2. Injectable
14.7.2.4.3. Others
14.7.2.5. The UK Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
14.7.2.5.1. Online
14.7.2.5.2. Offline
14.7.3. Spain
14.7.3.1. Spain Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.7.3.1.1. 5-HT3 Receptor Antagonists
14.7.3.1.2. Cannabinoids
14.7.3.1.3. Benzodiazepines
14.7.3.1.4. Glucocorticoids
14.7.3.1.5. Dopamine Receptor Antagonists
14.7.3.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.3.1.7. Antihistamines
14.7.3.1.8. Others
14.7.3.2. Spain Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
14.7.3.2.1. Chemotherapy and Radiation therapy
14.7.3.2.2. Motion Sickness
14.7.3.2.3. Stomach Flu
14.7.3.2.4. Pregnancy
14.7.3.2.5. Gastroenteritis
14.7.3.2.6. Surgery
14.7.3.2.7. Others
14.7.3.3. Spain Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.7.3.3.1. Hospitals
14.7.3.3.2. Clinics
14.7.3.3.3. Pharmacies
14.7.3.3.4. Others
14.7.3.4. Spain Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.3.4.1. Oral
14.7.3.4.2. Injectable
14.7.3.4.3. Others
14.7.3.5. Spain Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
14.7.3.5.1. Online
14.7.3.5.2. Offline
14.7.4. Germany
14.7.4.1. Germany Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
14.7.4.1.1. 5-HT3 Receptor Antagonists
14.7.4.1.2. Cannabinoids
14.7.4.1.3. Benzodiazepines
14.7.4.1.4. Glucocorticoids
14.7.4.1.5. Dopamine Receptor Antagonists
14.7.4.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.4.1.7. Antihistamines
14.7.4.1.8. Others
14.7.4.2. Germany Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.4.2.1. Chemotherapy and Radiation therapy
14.7.4.2.2. Motion Sickness
14.7.4.2.3. Stomach Flu
14.7.4.2.4. Pregnancy
14.7.4.2.5. Gastroenteritis
14.7.4.2.6. Surgery
14.7.4.2.7. Others
14.7.4.3. Germany Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
14.7.4.3.1. Hospitals
14.7.4.3.2. Clinics
14.7.4.3.3. Pharmacies
14.7.4.3.4. Others
14.7.4.4. Germany Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.4.4.1. Oral
14.7.4.4.2. Injectable
14.7.4.4.3. Others
14.7.4.5. Germany Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
14.7.4.5.1. Online
14.7.4.5.2. Offline
14.7.5. Italy
14.7.5.1. Italy Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.7.5.1.1. 5-HT3 Receptor Antagonists
14.7.5.1.2. Cannabinoids
14.7.5.1.3. Benzodiazepines
14.7.5.1.4. Glucocorticoids
14.7.5.1.5. Dopamine Receptor Antagonists
14.7.5.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.5.1.7. Antihistamines
14.7.5.1.8. Others
14.7.5.2. Italy Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
14.7.5.2.1. Chemotherapy and Radiation therapy
14.7.5.2.2. Motion Sickness
14.7.5.2.3. Stomach Flu
14.7.5.2.4. Pregnancy
14.7.5.2.5. Gastroenteritis
14.7.5.2.6. Surgery
14.7.5.2.7. Others
14.7.5.3. Italy Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.7.5.3.1. Hospitals
14.7.5.3.2. Clinics
14.7.5.3.3. Pharmacies
14.7.5.3.4. Others
14.7.5.4. Italy Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.5.4.1. Oral
14.7.5.4.2. Injectable
14.7.5.4.3. Others
14.7.5.5. Italy Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
14.7.5.5.1. Online
14.7.5.5.2. Offline
14.7.6. Nordic Countries
14.7.6.1. Nordic Countries Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Drug Class
14.7.6.1.1. 5-HT3 Receptor Antagonists
14.7.6.1.2. Cannabinoids
14.7.6.1.3. Benzodiazepines
14.7.6.1.4. Glucocorticoids
14.7.6.1.5. Dopamine Receptor Antagonists
14.7.6.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.6.1.7. Antihistamines
14.7.6.1.8. Others
14.7.6.2. Nordic Countries Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Application
14.7.6.2.1. Chemotherapy and Radiation therapy
14.7.6.2.2. Motion Sickness
14.7.6.2.3. Stomach Flu
14.7.6.2.4. Pregnancy
14.7.6.2.5. Gastroenteritis
14.7.6.2.6. Surgery
14.7.6.2.7. Others
14.7.6.3. Nordic Countries Antiemetics Market Revenue
(US$ Mn) and Forecasts, By End-User
14.7.6.3.1. Hospitals
14.7.6.3.2. Clinics
14.7.6.3.3. Pharmacies
14.7.6.3.4. Others
14.7.6.4. Nordic Countries Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.7.6.4.1. Oral
14.7.6.4.2. Injectable
14.7.6.4.3. Others
14.7.6.5. Nordic Countries Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Sales Channel
14.7.6.5.1. Online
14.7.6.5.2. Offline
14.7.6.6. Nordic Countries Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux Union
14.7.7.1. Benelux Union Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
14.7.7.1.1. 5-HT3 Receptor Antagonists
14.7.7.1.2. Cannabinoids
14.7.7.1.3. Benzodiazepines
14.7.7.1.4. Glucocorticoids
14.7.7.1.5. Dopamine Receptor Antagonists
14.7.7.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.7.1.7. Antihistamines
14.7.7.1.8. Others
14.7.7.2. Benelux Union Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
14.7.7.2.1. Chemotherapy and Radiation therapy
14.7.7.2.2. Motion Sickness
14.7.7.2.3. Stomach Flu
14.7.7.2.4. Pregnancy
14.7.7.2.5. Gastroenteritis
14.7.7.2.6. Surgery
14.7.7.2.7. Others
14.7.7.3. Benelux Union Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
14.7.7.3.1. Hospitals
14.7.7.3.2. Clinics
14.7.7.3.3. Pharmacies
14.7.7.3.4. Others
14.7.7.4. Benelux Union Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.7.7.4.1. Oral
14.7.7.4.2. Injectable
14.7.7.4.3. Others
14.7.7.5. Benelux Union Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
14.7.7.5.1. Online
14.7.7.5.2. Offline
14.7.7.6. Benelux Union Antiemetics Market Revenue (US$
Mn) and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of Europe
14.7.8.1. Rest of Europe Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Drug Class
14.7.8.1.1. 5-HT3 Receptor Antagonists
14.7.8.1.2. Cannabinoids
14.7.8.1.3. Benzodiazepines
14.7.8.1.4. Glucocorticoids
14.7.8.1.5. Dopamine Receptor Antagonists
14.7.8.1.6. Neurokinin (NK1) Receptor Antagonists
14.7.8.1.7. Antihistamines
14.7.8.1.8. Others
14.7.8.2. Rest of Europe Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Application
14.7.8.2.1. Chemotherapy and Radiation therapy
14.7.8.2.2. Motion Sickness
14.7.8.2.3. Stomach Flu
14.7.8.2.4. Pregnancy
14.7.8.2.5. Gastroenteritis
14.7.8.2.6. Surgery
14.7.8.2.7. Others
14.7.8.3. Rest of Europe Antiemetics Market Revenue
(US$ Mn) and Forecasts, By End-User
14.7.8.3.1. Hospitals
14.7.8.3.2. Clinics
14.7.8.3.3. Pharmacies
14.7.8.3.4. Others
14.7.8.4. Rest of Europe Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.7.8.4.1. Oral
14.7.8.4.2. Injectable
14.7.8.4.3. Others
14.7.8.5. Rest of Europe Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Sales Channel
14.7.8.5.1. Online
14.7.8.5.2. Offline
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Drug Class
14.8.3. By Application
14.8.4. By End-User
14.8.5. By Route of Administration
14.8.6. By Sales Channel
15. Asia Pacific Antiemetics Market Analysis and
Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Asia Pacific Antiemetics Market Revenue (US$
Mn)
15.2. Asia Pacific Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
15.2.1. 5-HT3 Receptor Antagonists
15.2.2. Cannabinoids
15.2.3. Benzodiazepines
15.2.4. Glucocorticoids
15.2.5. Dopamine Receptor Antagonists
15.2.6. Neurokinin (NK1) Receptor Antagonists
15.2.7. Antihistamines
15.2.8. Others
15.3. Asia Pacific Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
15.3.1. Chemotherapy and Radiation therapy
15.3.2. Motion Sickness
15.3.3. Stomach Flu
15.3.4. Pregnancy
15.3.5. Gastroenteritis
15.3.6. Surgery
15.3.7. Others
15.4. Asia Pacific Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
15.4.1. Hospitals
15.4.2. Clinics
15.4.3. Pharmacies
15.4.4. Others
15.5. Asia Pacific Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.5.1. Oral
15.5.2. Injectable
15.5.3. Others
15.6. Asia Pacific Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
15.6.1. Online
15.6.2. Offline
15.7. Asia Pacific Antiemetics Market Revenue (US$
Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1. China Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.7.1.1.1. 5-HT3 Receptor Antagonists
15.7.1.1.2. Cannabinoids
15.7.1.1.3. Benzodiazepines
15.7.1.1.4. Glucocorticoids
15.7.1.1.5. Dopamine Receptor Antagonists
15.7.1.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.1.1.7. Antihistamines
15.7.1.1.8. Others
15.7.1.2. China Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.1.2.1. Chemotherapy and Radiation therapy
15.7.1.2.2. Motion Sickness
15.7.1.2.3. Stomach Flu
15.7.1.2.4. Pregnancy
15.7.1.2.5. Gastroenteritis
15.7.1.2.6. Surgery
15.7.1.2.7. Others
15.7.1.3. China Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
15.7.1.3.1. Hospitals
15.7.1.3.2. Clinics
15.7.1.3.3. Pharmacies
15.7.1.3.4. Others
15.7.1.4. China Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.1.4.1. Oral
15.7.1.4.2. Injectable
15.7.1.4.3. Others
15.7.1.5. China Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
15.7.1.5.1. Online
15.7.1.5.2. Offline
15.7.2. Japan
15.7.2.1. Japan Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.7.2.1.1. 5-HT3 Receptor Antagonists
15.7.2.1.2. Cannabinoids
15.7.2.1.3. Benzodiazepines
15.7.2.1.4. Glucocorticoids
15.7.2.1.5. Dopamine Receptor Antagonists
15.7.2.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.2.1.7. Antihistamines
15.7.2.1.8. Others
15.7.2.2. Japan Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.2.2.1. Chemotherapy and Radiation therapy
15.7.2.2.2. Motion Sickness
15.7.2.2.3. Stomach Flu
15.7.2.2.4. Pregnancy
15.7.2.2.5. Gastroenteritis
15.7.2.2.6. Surgery
15.7.2.2.7. Others
15.7.2.3. Japan Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
15.7.2.3.1. Hospitals
15.7.2.3.2. Clinics
15.7.2.3.3. Pharmacies
15.7.2.3.4. Others
15.7.2.4. Japan Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.2.4.1. Oral
15.7.2.4.2. Injectable
15.7.2.4.3. Others
15.7.2.5. Japan Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
15.7.2.5.1. Online
15.7.2.5.2. Offline
15.7.3. India
15.7.3.1. India Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.7.3.1.1. 5-HT3 Receptor Antagonists
15.7.3.1.2. Cannabinoids
15.7.3.1.3. Benzodiazepines
15.7.3.1.4. Glucocorticoids
15.7.3.1.5. Dopamine Receptor Antagonists
15.7.3.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.3.1.7. Antihistamines
15.7.3.1.8. Others
15.7.3.2. India Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.3.2.1. Chemotherapy and Radiation therapy
15.7.3.2.2. Motion Sickness
15.7.3.2.3. Stomach Flu
15.7.3.2.4. Pregnancy
15.7.3.2.5. Gastroenteritis
15.7.3.2.6. Surgery
15.7.3.2.7. Others
15.7.3.3. India Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
15.7.3.3.1. Hospitals
15.7.3.3.2. Clinics
15.7.3.3.3. Pharmacies
15.7.3.3.4. Others
15.7.3.4. India Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.3.4.1. Oral
15.7.3.4.2. Injectable
15.7.3.4.3. Others
15.7.3.5. India Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
15.7.3.5.1. Online
15.7.3.5.2. Offline
15.7.4. New Zealand
15.7.4.1. New Zealand Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
15.7.4.1.1. 5-HT3 Receptor Antagonists
15.7.4.1.2. Cannabinoids
15.7.4.1.3. Benzodiazepines
15.7.4.1.4. Glucocorticoids
15.7.4.1.5. Dopamine Receptor Antagonists
15.7.4.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.4.1.7. Antihistamines
15.7.4.1.8. Others
15.7.4.2. New Zealand Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
15.7.4.2.1. Chemotherapy and Radiation therapy
15.7.4.2.2. Motion Sickness
15.7.4.2.3. Stomach Flu
15.7.4.2.4. Pregnancy
15.7.4.2.5. Gastroenteritis
15.7.4.2.6. Surgery
15.7.4.2.7. Others
15.7.4.3. New Zealand Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
15.7.4.3.1. Hospitals
15.7.4.3.2. Clinics
15.7.4.3.3. Pharmacies
15.7.4.3.4. Others
15.7.4.4. New Zealand Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.7.4.4.1. Oral
15.7.4.4.2. Injectable
15.7.4.4.3. Others
15.7.4.5. New Zealand Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
15.7.4.5.1. Online
15.7.4.5.2. Offline
15.7.5. Australia
15.7.5.1. Australia Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
15.7.5.1.1. 5-HT3 Receptor Antagonists
15.7.5.1.2. Cannabinoids
15.7.5.1.3. Benzodiazepines
15.7.5.1.4. Glucocorticoids
15.7.5.1.5. Dopamine Receptor Antagonists
15.7.5.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.5.1.7. Antihistamines
15.7.5.1.8. Others
15.7.5.2. Australia Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
15.7.5.2.1. Chemotherapy and Radiation therapy
15.7.5.2.2. Motion Sickness
15.7.5.2.3. Stomach Flu
15.7.5.2.4. Pregnancy
15.7.5.2.5. Gastroenteritis
15.7.5.2.6. Surgery
15.7.5.2.7. Others
15.7.5.3. Australia Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
15.7.5.3.1. Hospitals
15.7.5.3.2. Clinics
15.7.5.3.3. Pharmacies
15.7.5.3.4. Others
15.7.5.4. Australia Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.7.5.4.1. Oral
15.7.5.4.2. Injectable
15.7.5.4.3. Others
15.7.5.5. Australia Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
15.7.5.5.1. Online
15.7.5.5.2. Offline
15.7.6. South Korea
15.7.6.1. South Korea Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
15.7.6.1.1. 5-HT3 Receptor Antagonists
15.7.6.1.2. Cannabinoids
15.7.6.1.3. Benzodiazepines
15.7.6.1.4. Glucocorticoids
15.7.6.1.5. Dopamine Receptor Antagonists
15.7.6.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.6.1.7. Antihistamines
15.7.6.1.8. Others
15.7.6.2. South Korea Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
15.7.6.2.1. Chemotherapy and Radiation therapy
15.7.6.2.2. Motion Sickness
15.7.6.2.3. Stomach Flu
15.7.6.2.4. Pregnancy
15.7.6.2.5. Gastroenteritis
15.7.6.2.6. Surgery
15.7.6.2.7. Others
15.7.6.3. South Korea Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
15.7.6.3.1. Hospitals
15.7.6.3.2. Clinics
15.7.6.3.3. Pharmacies
15.7.6.3.4. Others
15.7.6.4. South Korea Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.7.6.4.1. Oral
15.7.6.4.2. Injectable
15.7.6.4.3. Others
15.7.6.5. South Korea Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
15.7.6.5.1. Online
15.7.6.5.2. Offline
15.7.7. Southeast Asia
15.7.7.1. Southeast Asia Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Drug Class
15.7.7.1.1. 5-HT3 Receptor Antagonists
15.7.7.1.2. Cannabinoids
15.7.7.1.3. Benzodiazepines
15.7.7.1.4. Glucocorticoids
15.7.7.1.5. Dopamine Receptor Antagonists
15.7.7.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.7.1.7. Antihistamines
15.7.7.1.8. Others
15.7.7.2. Southeast Asia Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Application
15.7.7.2.1. Chemotherapy and Radiation therapy
15.7.7.2.2. Motion Sickness
15.7.7.2.3. Stomach Flu
15.7.7.2.4. Pregnancy
15.7.7.2.5. Gastroenteritis
15.7.7.2.6. Surgery
15.7.7.2.7. Others
15.7.7.3. Southeast Asia Antiemetics Market Revenue
(US$ Mn) and Forecasts, By End-User
15.7.7.3.1. Hospitals
15.7.7.3.2. Clinics
15.7.7.3.3. Pharmacies
15.7.7.3.4. Others
15.7.7.4. Southeast Asia Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.7.7.4.1. Oral
15.7.7.4.2. Injectable
15.7.7.4.3. Others
15.7.7.5. Southeast Asia Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Sales Channel
15.7.7.5.1. Online
15.7.7.5.2. Offline
15.7.7.6. Southeast Asia Antiemetics Market Revenue
(US$ Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest of Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1. Rest of Asia Pacific Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.8.1.1. 5-HT3 Receptor Antagonists
15.7.8.1.2. Cannabinoids
15.7.8.1.3. Benzodiazepines
15.7.8.1.4. Glucocorticoids
15.7.8.1.5. Dopamine Receptor Antagonists
15.7.8.1.6. Neurokinin (NK1) Receptor Antagonists
15.7.8.1.7. Antihistamines
15.7.8.1.8. Others
15.7.8.2. Rest of Asia Pacific Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.8.2.1. Chemotherapy and Radiation therapy
15.7.8.2.2. Motion Sickness
15.7.8.2.3. Stomach Flu
15.7.8.2.4. Pregnancy
15.7.8.2.5. Gastroenteritis
15.7.8.2.6. Surgery
15.7.8.2.7. Others
15.7.8.3. Rest of Asia Pacific Antiemetics Market
Revenue (US$ Mn) and Forecasts, By End-User
15.7.8.3.1. Hospitals
15.7.8.3.2. Clinics
15.7.8.3.3. Pharmacies
15.7.8.3.4. Others
15.7.8.4. Rest of Asia Pacific Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.8.4.1. Oral
15.7.8.4.2. Injectable
15.7.8.4.3. Others
15.7.8.5. Rest of Asia Pacific Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.8.5.1. Online
15.7.8.5.2. Offline
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Drug Class
15.8.3. By Application
15.8.4. By End-User
15.8.5. By Route of Administration
15.8.6. By Sales Channel
16. Middle East and Africa Antiemetics Market
Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Middle East and Africa Antiemetics Market
Revenue (US$ Mn)
16.2. Middle East and Africa Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
16.2.1. 5-HT3 Receptor Antagonists
16.2.2. Cannabinoids
16.2.3. Benzodiazepines
16.2.4. Glucocorticoids
16.2.5. Dopamine Receptor Antagonists
16.2.6. Neurokinin (NK1) Receptor Antagonists
16.2.7. Antihistamines
16.2.8. Others
16.3. Middle East and Africa Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Application
16.3.1. Chemotherapy and Radiation therapy
16.3.2. Motion Sickness
16.3.3. Stomach Flu
16.3.4. Pregnancy
16.3.5. Gastroenteritis
16.3.6. Surgery
16.3.7. Others
16.4. Middle East and Africa Antiemetics Market
Revenue (US$ Mn) and Forecasts, By End-User
16.4.1. Hospitals
16.4.2. Clinics
16.4.3. Pharmacies
16.4.4. Others
16.5. Middle East and Africa Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.5.1. Oral
16.5.2. Injectable
16.5.3. Others
16.6. Middle East and Africa Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Sales Channel
16.6.1. Online
16.6.2. Offline
16.7. Middle East and Africa Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1. Saudi Arabia Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
16.7.1.1.1. 5-HT3 Receptor Antagonists
16.7.1.1.2. Cannabinoids
16.7.1.1.3. Benzodiazepines
16.7.1.1.4. Glucocorticoids
16.7.1.1.5. Dopamine Receptor Antagonists
16.7.1.1.6. Neurokinin (NK1) Receptor Antagonists
16.7.1.1.7. Antihistamines
16.7.1.1.8. Others
16.7.1.2. Saudi Arabia Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
16.7.1.2.1. Chemotherapy and Radiation therapy
16.7.1.2.2. Motion Sickness
16.7.1.2.3. Stomach Flu
16.7.1.2.4. Pregnancy
16.7.1.2.5. Gastroenteritis
16.7.1.2.6. Surgery
16.7.1.2.7. Others
16.7.1.3. Saudi Arabia Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
16.7.1.3.1. Hospitals
16.7.1.3.2. Clinics
16.7.1.3.3. Pharmacies
16.7.1.3.4. Others
16.7.1.4. Saudi Arabia Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.7.1.4.1. Oral
16.7.1.4.2. Injectable
16.7.1.4.3. Others
16.7.1.5. Saudi Arabia Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
16.7.1.5.1. Online
16.7.1.5.2. Offline
16.7.2. UAE
16.7.2.1. UAE Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
16.7.2.1.1. 5-HT3 Receptor Antagonists
16.7.2.1.2. Cannabinoids
16.7.2.1.3. Benzodiazepines
16.7.2.1.4. Glucocorticoids
16.7.2.1.5. Dopamine Receptor Antagonists
16.7.2.1.6. Neurokinin (NK1) Receptor Antagonists
16.7.2.1.7. Antihistamines
16.7.2.1.8. Others
16.7.2.2. UAE Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
16.7.2.2.1. Chemotherapy and Radiation therapy
16.7.2.2.2. Motion Sickness
16.7.2.2.3. Stomach Flu
16.7.2.2.4. Pregnancy
16.7.2.2.5. Gastroenteritis
16.7.2.2.6. Surgery
16.7.2.2.7. Others
16.7.2.3. UAE Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
16.7.2.3.1. Hospitals
16.7.2.3.2. Clinics
16.7.2.3.3. Pharmacies
16.7.2.3.4. Others
16.7.2.4. UAE Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.2.4.1. Oral
16.7.2.4.2. Injectable
16.7.2.4.3. Others
16.7.2.5. UAE Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
16.7.2.5.1. Online
16.7.2.5.2. Offline
16.7.3. Egypt
16.7.3.1. Egypt Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
16.7.3.1.1. 5-HT3 Receptor Antagonists
16.7.3.1.2. Cannabinoids
16.7.3.1.3. Benzodiazepines
16.7.3.1.4. Glucocorticoids
16.7.3.1.5. Dopamine Receptor Antagonists
16.7.3.1.6. Neurokinin (NK1) Receptor Antagonists
16.7.3.1.7. Antihistamines
16.7.3.1.8. Others
16.7.3.2. Egypt Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Application
16.7.3.2.1. Chemotherapy and Radiation therapy
16.7.3.2.2. Motion Sickness
16.7.3.2.3. Stomach Flu
16.7.3.2.4. Pregnancy
16.7.3.2.5. Gastroenteritis
16.7.3.2.6. Surgery
16.7.3.2.7. Others
16.7.3.3. Egypt Antiemetics Market Revenue (US$ Mn) and
Forecasts, By End-User
16.7.3.3.1. Hospitals
16.7.3.3.2. Clinics
16.7.3.3.3. Pharmacies
16.7.3.3.4. Others
16.7.3.4. Egypt Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.3.4.1. Oral
16.7.3.4.2. Injectable
16.7.3.4.3. Others
16.7.3.5. Egypt Antiemetics Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
16.7.3.5.1. Online
16.7.3.5.2. Offline
16.7.4. Kuwait
16.7.4.1. Kuwait Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
16.7.4.1.1. 5-HT3 Receptor Antagonists
16.7.4.1.2. Cannabinoids
16.7.4.1.3. Benzodiazepines
16.7.4.1.4. Glucocorticoids
16.7.4.1.5. Dopamine Receptor Antagonists
16.7.4.1.6. Neurokinin (NK1) Receptor Antagonists
16.7.4.1.7. Antihistamines
16.7.4.1.8. Others
16.7.4.2. Kuwait Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
16.7.4.2.1. Chemotherapy and Radiation therapy
16.7.4.2.2. Motion Sickness
16.7.4.2.3. Stomach Flu
16.7.4.2.4. Pregnancy
16.7.4.2.5. Gastroenteritis
16.7.4.2.6. Surgery
16.7.4.2.7. Others
16.7.4.3. Kuwait Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
16.7.4.3.1. Hospitals
16.7.4.3.2. Clinics
16.7.4.3.3. Pharmacies
16.7.4.3.4. Others
16.7.4.4. Kuwait Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
16.7.4.4.1. Oral
16.7.4.4.2. Injectable
16.7.4.4.3. Others
16.7.4.5. Kuwait Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
16.7.4.5.1. Online
16.7.4.5.2. Offline
16.7.5. South Africa
16.7.5.1. South Africa Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
16.7.5.1.1. 5-HT3 Receptor Antagonists
16.7.5.1.2. Cannabinoids
16.7.5.1.3. Benzodiazepines
16.7.5.1.4. Glucocorticoids
16.7.5.1.5. Dopamine Receptor Antagonists
16.7.5.1.6. Neurokinin (NK1) Receptor Antagonists
16.7.5.1.7. Antihistamines
16.7.5.1.8. Others
16.7.5.2. South Africa Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
16.7.5.2.1. Chemotherapy and Radiation therapy
16.7.5.2.2. Motion Sickness
16.7.5.2.3. Stomach Flu
16.7.5.2.4. Pregnancy
16.7.5.2.5. Gastroenteritis
16.7.5.2.6. Surgery
16.7.5.2.7. Others
16.7.5.3. South Africa Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
16.7.5.3.1. Hospitals
16.7.5.3.2. Clinics
16.7.5.3.3. Pharmacies
16.7.5.3.4. Others
16.7.5.4. South Africa Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.7.5.4.1. Oral
16.7.5.4.2. Injectable
16.7.5.4.3. Others
16.7.5.5. South Africa Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
16.7.5.5.1. Online
16.7.5.5.2. Offline
16.7.6. Rest of Middle East & Africa
16.7.6.1. Rest of Middle East & Africa Antiemetics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.6.1.1. 5-HT3 Receptor Antagonists
16.7.6.1.2. Cannabinoids
16.7.6.1.3. Benzodiazepines
16.7.6.1.4. Glucocorticoids
16.7.6.1.5. Dopamine Receptor Antagonists
16.7.6.1.6. Neurokinin (NK1) Receptor Antagonists
16.7.6.1.7. Antihistamines
16.7.6.1.8. Others
16.7.6.2. Rest of Middle East & Africa Antiemetics
Market Revenue (US$ Mn) and Forecasts, By Application
16.7.6.2.1. Chemotherapy and Radiation therapy
16.7.6.2.2. Motion Sickness
16.7.6.2.3. Stomach Flu
16.7.6.2.4. Pregnancy
16.7.6.2.5. Gastroenteritis
16.7.6.2.6. Surgery
16.7.6.2.7. Others
16.7.6.3. Rest of Middle East & Africa Antiemetics
Market Revenue (US$ Mn) and Forecasts, By End-User
16.7.6.3.1. Hospitals
16.7.6.3.2. Clinics
16.7.6.3.3. Pharmacies
16.7.6.3.4. Others
16.7.6.4. Rest of Middle East & Africa Antiemetics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.6.4.1. Oral
16.7.6.4.2. Injectable
16.7.6.4.3. Others
16.7.6.5. Rest of Middle East & Africa Antiemetics
Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.7.6.5.1. Online
16.7.6.5.2. Offline
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Drug Class
16.8.3. By Application
16.8.4. By End-User
16.8.5. By Route of Administration
16.8.6. By Sales Channel
17. Latin America Antiemetics Market Analysis
and Forecasts, 2022 - 2030
17.1. Overview
17.1.1. Latin America Antiemetics Market Revenue (US$
Mn)
17.2. Latin America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Drug Class
17.2.1. 5-HT3 Receptor Antagonists
17.2.2. Cannabinoids
17.2.3. Benzodiazepines
17.2.4. Glucocorticoids
17.2.5. Dopamine Receptor Antagonists
17.2.6. Neurokinin (NK1) Receptor Antagonists
17.2.7. Antihistamines
17.2.8. Others
17.3. Latin America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Application
17.3.1. Chemotherapy and Radiation therapy
17.3.2. Motion Sickness
17.3.3. Stomach Flu
17.3.4. Pregnancy
17.3.5. Gastroenteritis
17.3.6. Surgery
17.3.7. Others
17.4. Latin America Antiemetics Market Revenue (US$
Mn) and Forecasts, By End-User
17.4.1. Hospitals
17.4.2. Clinics
17.4.3. Pharmacies
17.4.4. Others
17.5. Latin America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Route of Administration
17.5.1. Oral
17.5.2. Injectable
17.5.3. Others
17.6. Latin America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Sales Channel
17.6.1. Online
17.6.2. Offline
17.7. Latin America Antiemetics Market Revenue (US$
Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
17.7.1.1.1. 5-HT3 Receptor Antagonists
17.7.1.1.2. Cannabinoids
17.7.1.1.3. Benzodiazepines
17.7.1.1.4. Glucocorticoids
17.7.1.1.5. Dopamine Receptor Antagonists
17.7.1.1.6. Neurokinin (NK1) Receptor Antagonists
17.7.1.1.7. Antihistamines
17.7.1.1.8. Others
17.7.1.2. Brazil Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
17.7.1.2.1. Chemotherapy and Radiation therapy
17.7.1.2.2. Motion Sickness
17.7.1.2.3. Stomach Flu
17.7.1.2.4. Pregnancy
17.7.1.2.5. Gastroenteritis
17.7.1.2.6. Surgery
17.7.1.2.7. Others
17.7.1.3. Brazil Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
17.7.1.3.1. Hospitals
17.7.1.3.2. Clinics
17.7.1.3.3. Pharmacies
17.7.1.3.4. Others
17.7.1.4. Brazil Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
17.7.1.4.1. Oral
17.7.1.4.2. Injectable
17.7.1.4.3. Others
17.7.1.5. Brazil Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
17.7.1.5.1. Online
17.7.1.5.2. Offline
17.7.2. Argentina
17.7.2.1. Argentina Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Drug Class
17.7.2.1.1. 5-HT3 Receptor Antagonists
17.7.2.1.2. Cannabinoids
17.7.2.1.3. Benzodiazepines
17.7.2.1.4. Glucocorticoids
17.7.2.1.5. Dopamine Receptor Antagonists
17.7.2.1.6. Neurokinin (NK1) Receptor Antagonists
17.7.2.1.7. Antihistamines
17.7.2.1.8. Others
17.7.2.2. Argentina Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Application
17.7.2.2.1. Chemotherapy and Radiation therapy
17.7.2.2.2. Motion Sickness
17.7.2.2.3. Stomach Flu
17.7.2.2.4. Pregnancy
17.7.2.2.5. Gastroenteritis
17.7.2.2.6. Surgery
17.7.2.2.7. Others
17.7.2.3. Argentina Antiemetics Market Revenue (US$ Mn)
and Forecasts, By End-User
17.7.2.3.1. Hospitals
17.7.2.3.2. Clinics
17.7.2.3.3. Pharmacies
17.7.2.3.4. Others
17.7.2.4. Argentina Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
17.7.2.4.1. Oral
17.7.2.4.2. Injectable
17.7.2.4.3. Others
17.7.2.5. Argentina Antiemetics Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
17.7.2.5.1. Online
17.7.2.5.2. Offline
17.7.3. Rest of Latin America
17.7.3.1. Rest of Latin America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
17.7.3.1.1. 5-HT3 Receptor Antagonists
17.7.3.1.2. Cannabinoids
17.7.3.1.3. Benzodiazepines
17.7.3.1.4. Glucocorticoids
17.7.3.1.5. Dopamine Receptor Antagonists
17.7.3.1.6. Neurokinin (NK1) Receptor Antagonists
17.7.3.1.7. Antihistamines
17.7.3.1.8. Others
17.7.3.2. Rest of Latin America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Application
17.7.3.2.1. Chemotherapy and Radiation therapy
17.7.3.2.2. Motion Sickness
17.7.3.2.3. Stomach Flu
17.7.3.2.4. Pregnancy
17.7.3.2.5. Gastroenteritis
17.7.3.2.6. Surgery
17.7.3.2.7. Others
17.7.3.3. Rest of Latin America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By End-User
17.7.3.3.1. Hospitals
17.7.3.3.2. Clinics
17.7.3.3.3. Pharmacies
17.7.3.3.4. Others
17.7.3.4. Rest of Latin America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.3.4.1. Oral
17.7.3.4.2. Injectable
17.7.3.4.3. Others
17.7.3.5. Rest of Latin America Antiemetics Market
Revenue (US$ Mn) and Forecasts, By Sales Channel
17.7.3.5.1. Online
17.7.3.5.2. Offline
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Drug Class
17.8.3. By Application
17.8.4. By End-User
17.8.5. By Route of Administration
17.8.6. By Sales Channel
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2021
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. Acacia Pharma Group Plc
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. Astellas Pharma Inc.
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. Aurobindo Pharma
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. Biostem Pharma
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. Dr. Reddy’s Laboratories Ltd.
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. Eisai Co., Ltd.
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. F.Hoffmann-La Roche Limited
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. Heron Therapeutics, Inc.
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. Merck & Co., Inc.
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4. Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10. Novartis
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11. PAX HEALTHCARE
19.11.1. Company Details
19.11.2. Company Overview
19.11.3. Product Offerings
19.11.4. Key Developments
19.11.5. Financial Analysis
19.11.6. SWOT Analysis
19.11.7. Business Strategies
19.12. Pfizer Inc
19.12.1. Company Details
19.12.2. Company Overview
19.12.3. Product Offerings
19.12.4. Key Developments
19.12.5. Financial Analysis
19.12.6. SWOT Analysis
19.12.7. Business Strategies
19.13. Sanofi S.A.
19.13.1. Company Details
19.13.2. Company Overview
19.13.3. Product Offerings
19.13.4. Key Developments
19.13.5. Financial Analysis
19.13.6. SWOT Analysis
19.13.7. Business Strategies
19.14. TerSera Therapeutics LLC
19.14.1. Company Details
19.14.2. Company Overview
19.14.3. Product Offerings
19.14.4. Key Developments
19.14.5. Financial Analysis
19.14.6. SWOT Analysis
19.14.7. Business Strategies
19.15. Teva Pharmaceutical Industries Ltd.
19.15.1. Company Details
19.15.2. Company Overview
19.15.3. Product Offerings
19.15.4. Key Developments
19.15.5. Financial Analysis
19.15.6. SWOT Analysis
19.15.7. Business Strategies
19.16. Other Market Participants
20. Key Findings
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.